Ovid Therapeutics Entered into an Exclusive License Agreement with AstraZeneca to Expand its Epilepsy Franchise with Novel KCC2 Activators
Shots:
- AstraZeneca will receive $5M upfront in cash and $7.5M in shares of Ovid common stock and is eligible to receive ~$8M as potential clinical development milestones and $45M in regulatory milestones
- Total commercial milestones can sum up to $150M and tiered royalty payments ranging from the single digits up to 10% on net sales. AstraZeneca will have the right of the first negotiation to opt-in on a strategic collaboration at the time of proof of clinical efficacy
- Additionally, the company is developing OV329 which is a next-gen pregabalin for tuberous sclerosis and infantile spasms, expected to enter the clinic in 2022. Earlier, Ovid licensed soticlestat which is currently being studied in P-III trials for Dravet and Lennox Gastaut syndromes
Ref: Ovid | Image: Ovid
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com